Seropositivity following mRNA vaccination for SARS-CoV-2 in patients undergoing cancer treatment
Published 2021-05-28 · Original archive entry · Explore research explainers
What The Study Did: Rates of antispike antibody response to a messenger RNA SARS-CoV-2 vaccine in Israeli patients with cancer who are undergoing systemic treatment compared with healthy controls were evaluated in this study.
Authors: Salomon M. Stemmer, M.D., of the Rabin Medical Center in Petah Tikva, Israel, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2021.2155)
Editor's Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Authors: Salomon M. Stemmer, M.D., of the Rabin Medical Center in Petah Tikva, Israel, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2021.2155)
Editor's Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
INFORMATION:
Media advisory: The full article and editorial are linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2021.2155?guestAccessKey=41cd3cc4-ce5f-4607-9680-86c094b38c0a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053121